This article is more than 5 years old. Information may no longer be current.

B&L announces Medicare reimbursement for Retisert

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCHESTER, N.Y. — An intravitreal implant for the treatment of chronic noninfectious uveitis affecting the posterior segment will have a Medicare payment rate of almost $20,000 when used in a hospital outpatient setting, according to a press release from Bausch & Lomb.

B&L said the Retisert payment methodology is based upon 106% of wholesale acquisition cost. The Centers for Medicare & Medicaid Services has designated the single-indication orphan drug as eligible for Medicare pass-through payment under the Hospital Outpatient Prospective Payment System effective Oct. 1.

Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg was launched in the United States in June, following approval by the Food and Drug Administration in April.